U.S. FDA to review Perrigo's birth control pill for OTC use in November
Reuters
Published Sep 12, 2022 10:45AM ET
Updated Sep 12, 2022 12:30PM ET
(Reuters) -Perrigo Co Plc said on Monday that the U.S. Food and Drug Administration has scheduled a meeting of external experts on Nov. 18 to review the application of its daily birth control pill for over-the-counter (OTC) use.
Contraception access has taken the spotlight since the U.S. Supreme Court's decision in June to overturn the 1973 Roe v. Wade case that legalized abortion nationwide.
The FDA meeting for Perrigo's prescription drug, Opill, is set to happen about four months after unit HRA Pharma's application to the health agency. If approved, it will be the first daily OTC birth control pill in the United States.
"While this (the review) is moving quickly, FDA confirmed this is still within timelines of a standard review," a spokesperson for HRA said. Perrigo's unit had earlier said a period of about 10 months is typical for such requests and that it was expecting a decision from the health regulator in the first half of 2023.
"I'm hopeful that the FDA will get to a point where they will agree with the evidence that already exists to show that over-the-counter birth control is safe and effective," said Dr. Kristyn Brandi, a member of the American College of Obstetricians and Gynecologists.
Abortion rights activists have also stepped up calls to make abortion drug mifepristone available without a prescription. Mifepristone in combination with misoprostol induces an abortion up to 10 weeks into a pregnancy.
Opill, a non-estrogen contraceptive, has been used with prescription since its approval in 1973.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.